LINDLEY DAVID J.,TONG PING,RÖSCH ESTHER,HOELIG PETER,SANZGIRI YESHWANT D.
申请号：
NZ60890711
公开号：
NZ608907A
申请日:
2011.10.05
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
The disclosure relates to a pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of formula (I) as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of formula (I), the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture； extruding the semi-solid mixture； and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.
